*Table 1*. CRN Shared Database Core Dataset Survey Results.

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **>70% respondents viewed as critical (n=27)** | | | | | | **50-70% respondents viewed as critical (n=17)** | | | | | | | | | |
|  | | * Demographics | | | |  | | | | | * Alcohol history | | | | |
|  | | * Smoking history | | | |  | | | | | * Chronic back pain details | | | | |
|  | | * Family history (of psoriasis, PsA, AS, SpA, IBD) | | | |  | | | | | * PsA subtype (poly, oligo, mutilans, axial predominant, DIP predominant) | | | | |
|  | | * Extra articular features (IBD, uveitis) | | | |  | | | | |  | | | | |
|  | | * Musculoskeletal history (current and previous) | | | |  | | | | |  | | | | |
|  | | * Skin history | | | |  | | | | |  | | | | |
|  | | * Date of diagnosis (year) psoriasis and PsA | | | |  | | | | |  | | | | |
|  | | * CASPAR criteria | | | |  | | | | |  | | | | |
|  | **Co-morbidities** | | | | |  | **Co-morbidities** | | | | | | | | |
|  | | * Obesity | | | |  | | | | | * Hypertension | | | | |
|  | | | | | |  | | | | | * Diabetes | | | | |
|  | | | | | |  | | | | | * Hyperlipidaemia | | | | |
|  | | | | | |  | | | | | * Previous cardiovascular event | | | | |
|  | | | | | |  | | | | | * Depression | | | | |
|  | **Medication** | | | | |  | **Medication** | | | | | | | | |
|  | | * Previous medicines | | | |  | | | | | | | | | |
|  | | * Current medicines | | | |  | | | | | | | | | |
|  | **Psoriasis\*** | | | | |  | **Psoriasis** | | | | | | | | |
|  | | | | | |  | | | | | * BSA | | | | |
|  | | **Nails\*** | | | |  | **Nails** | | | | | | | | |
|  | | | | | |  | | | | | * Nail pitting | | | | |
|  | | | | | |  | | | | | * Onycholysis | | | | |
|  | **Enthesitis\*** | | | | |  | | | | **Enthesitis** | | | | | |
|  | | | | | |  | | | | | | * LEI | | | |
|  | **Dactylitis** | | | | |  | | | **Dactylitis** | | | | | | |
|  | | | * Tender dactylitis count | | |  | | | | | | | | | |
|  | **Joint count** | | | | |  | | | **Joint count** | | | | | | |
|  | | | * 68 Tender joint count | | |  | | | | | | | | | |
|  | | | * 66 Swollen joint count | | |  | | | | | | | | | |
|  | **Physicians Global Assessment** | | | | |  | | | **Physicians Global Assessment** | | | | | | |
|  | | | * Global disease activity | | |  | | | | | | | * Arthritis activity | | |
|  | | | | | |  | | | | | | | * Skin disease | | |
|  | **Axial disease** | | | | |  | | | **Axial disease** | | | | | | |
|  | | | * BASDAI | | |  | | | | | | | | | |
|  | **Composite measures** | | | | |  | | | **Composite measures** | | | | | | |
|  | | | * MDA | | |  | | | | | | | | | |
|  | **PROMs** | | | | |  | | | **PROMs** | | | | | | |
|  | | | * BASDAI (if IBP symptoms) | | |  | | | | | | | | * Patient VAS: global disease | |
|  | | | * DLQI | | |  | | | | | | | | * Patient VAS: global pain | |
|  | | | * mHAQ | | |  | | | | | | | | * mHAQ | |
|  | | | * Patient global assessment of joint disease | | |  | | | | | | | |  | |
|  | | | * Patient global assessment of skin disease | | |  | | | | | | | |  | |
|  | | | * PsAID12 | | |  | | | | | | | |  | |
|  | **LABs** | | | | |  | | **LABs** | | | | | | | |
|  | | | | * ACPA (level and unit) | |  | | | | | | | | | * ESR |
|  | | | | | * Rheumatoid factor (level and unit) |  | | | | | | | | |  |
|  | | | | | * HLA-B27 |  | | | | | | | | |  |
|  | | | | | * CRP (level and unit) |  | | | | | | | | |  |

CRN: Collaborative Research Network; n: number; PsA: psoriatic arthritis; AS: ankylosing spondylitis; SpA: spondyloarthritis; IBD: inflammatory bowel disease; DIP: distal interphalangeal; CASPAR: ClASsification for PsA; BSA: body surface area; LEI: Leeds Enthesitis Index; BASDAI: Bath Ankylosing Spondylitis Disease Activity Index; MDA: minimal disease activity; PROMs: Patient-Reported Outcome Measures; IBP: inflammatory back pain; VAS: visual analog scale; DLQI: Dermatology Life Quality Index; mHAQ: modified Health Assessment Questionnaire; PsAID12: Psoriatic Arthritis Impact of Disease questionnaire; ACPA: anti-citrullinated protein antibodies; ESR: erythrocyte sedimentation rate; HLA-B27: human leukocyte antigen-B27; CRP: C-reactive protein.

\* >70% respondents agreed that domain items should be included, but there was no consensus on which instrument items to include.